Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Xencor, Inc.
Daiichi Sankyo
RAPT Therapeutics, Inc.
Xencor, Inc.
NextCure, Inc.
OncoNano Medicine, Inc.
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Nektar Therapeutics
Herlev Hospital
Xencor, Inc.
Ludwig Institute for Cancer Research
Incyte Corporation
Bayer
Incyte Corporation
Incyte Corporation
Kantonsspital Winterthur KSW
Corcept Therapeutics